相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial
Cunte Chen et al.
JCI INSIGHT (2022)
Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival
Ana Casal-Mourino et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes
Si-Yang Liu et al.
NATURE COMMUNICATIONS (2021)
FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer
Yue Guan et al.
FRONTIERS IN ONCOLOGY (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study
Liwen Xiong et al.
ONCOLOGIST (2019)
Recent trends in the treatment of unresectable stage III non-small-cell lung cancer
Go Makimoto et al.
RESPIRATORY INVESTIGATION (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection
Yi-Long Wu et al.
CLINICAL LUNG CANCER (2018)
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Wen-Zhao Zhong et al.
LANCET ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN) a randomised, open-label, phase 2 trial
Dongsheng Yue et al.
LANCET RESPIRATORY MEDICINE (2018)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated meta-analysis
Yonggang Yuan et al.
JOURNAL OF THORACIC DISEASE (2017)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
Karen Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status
Wenzhao Zhong et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
The International Association for the Study of Lung Cancer Lung Cancer Staging Project Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer
Hisao Asamura et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
Matthew G. Oser et al.
LANCET ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-Small-Cell Lung Cancer
Giorgio V. Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Evolving Role of Targeted Therapy in Early-Stage and Locally Advanced Non-small Cell Lung Cancer
Howard West
CURRENT ONCOLOGY REPORTS (2011)
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data
A. Auperin et al.
LANCET (2010)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group
Jean-Pierre Pignon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
分享论文
